Edwards Lifesciences Advances Structural Heart Care Through Innovation and Purpose
MWN-AI** Summary
At the conclusion of Heart Month, Edwards Lifesciences (NYSE: EW) reinforced its role as a leader in structural heart care, emphasizing its dedication to innovation and patient access. The company announced its ambitious goal to support an additional 2 million patients worldwide facing barriers to lifesaving structural heart treatments by 2030 through its global health initiative, Every Heartbeat Matters. This initiative aligns with Edwards' nearly 70-year mission to improve the lives of patients with structural heart disease, led by CEO Bernard Zovighian, who highlighted the profound impact of their innovations on individuals and communities.
Every Heartbeat Matters, supported by the Edwards Lifesciences Foundation, is particularly focused on increasing access to diagnosis and treatment for underserved patients in low- and middle-income regions. Since its inception in 2014, the program has reached over 4 million patients globally, addressing critical barriers to care including financial, systemic, and geographical challenges. Zovighian emphasized that the company's purpose is driven by a commitment to science and patient-centered care, stating that each advancement made by Edwards translates into meaningful improvements for patients.
Through strong partnerships across the healthcare ecosystem, Edwards Lifesciences continues to lead the way in structural heart technology and innovation. The company's deep expertise and proactive efforts to break down barriers allow them to provide transformative care to those in need. As it moves forward, Edwards remains committed to leveraging science and innovation to enhance the lives of patients worldwide, striving not only to advance technology but to ensure equitable access to care for all. For more information on their initiatives and impact, visit edwards.com and everyheartbeatmatters.org.
MWN-AI** Analysis
Edwards Lifesciences (NYSE: EW) is at the forefront of structural heart innovation, making significant strides in enhancing patient care for those with structural heart diseases. As the company emphasizes its commitment through initiatives like "Every Heartbeat Matters," which aims to help 2 million underserved patients access vital treatments by the end of 2030, investors should consider several positive aspects that could influence market performance.
Firstly, the long-standing history of Edwards, with nearly 70 years of expertise in the market, signifies a well-established brand known for its innovation and commitment. The ongoing emphasis on research and development is likely to yield advanced therapies that could set new standards in the industry, ultimately capturing a greater market share.
Secondly, the strategic partnerships Edwards has created within the global healthcare ecosystem enhance its credibility and expand its reach. Collaborations with healthcare providers ensure a deeper understanding of market needs and may lead to more effective solutions tailored to patient needs, bolstering sales growth.
Moreover, the initiative to break down barriers in access to care, especially in low- and middle-income regions, positions Edwards not only as a market leader but also as a socially responsible entity. This dual focus on profit and purpose can positively influence public perception, potentially leading to higher demand for products and services.
However, investors should approach with some caution. As the company acknowledges in its forward-looking statements, uncertainties and risks exist that may affect actual results compared to projections. Financial analysts should monitor performance metrics closely and stay informed about regulatory challenges and competitive pressures that could impact Edwards’ ability to maintain its leadership status.
In conclusion, Edwards Lifesciences represents a compelling investment opportunity for those interested in the healthcare sector, driven by innovation and a strong mission to improve patient lives. Balancing this potential with an awareness of the inherent risks will be crucial for judicious investment strategy.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
At the close of Heart Month, Edwards Lifesciences (NYSE: EW) underscored its leadership in structural heart innovation, advancing care through deep expertise and strong partnerships so people with structural heart disease can live longer, healthier lives. As part of this commitment, Edwards announced the impact and renewed vision for Every Heartbeat Matters, its signature global health initiative, to help 2 million more patients facing barriers worldwide access lifesaving structural heart treatment by the end of 2030.
“For nearly 70 years, Edwards has led with a strong focus on improving the lives of patients with structural heart disease,” said Bernard Zovighian, Edwards’ CEO. “It starts with breakthrough innovation, layered with world class clinical expertise, sustained commitment and strong partnerships across the global healthcare ecosystem. Every advancement we make impacts a patient, a family and a community. Our purpose is to advance science and expand access so more people can benefit.”
This commitment extends through the Edwards Lifesciences Foundation and Every Heartbeat Matters, which increases access to diagnosis and treatment for underserved structural heart patients, particularly those in low- and middle-income countries and regions where care is limited and barriers may be substantial. Since 2014, Every Heartbeat Matters and its charitable partners have impacted more than 4 million underserved structural heart patients globally.
“Improving the lives of patients with structural heart disease is core to who we are,” Zovighian said. “Through Every Heartbeat Matters and our global partners, we are breaking down financial, systemic and geographic barriers so that underserved patients can get access to care that can change the trajectory of their lives. We innovate with purpose, we are powered by science and we remain centered on patients.”
More information on the Edwards Lifesciences Foundation and Every Heartbeat Matters is available at www.edwards.com/corporategiving or www.everyheartbeatmatters.org .
About Edwards Lifesciences
Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at www.edwards.com and follow us on LinkedIn, Facebook, Instagram and YouTube.
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements can sometimes be identified by the use of words such as “may,” “will,” “should,” “anticipate,” “believe,” “plan,” “project,” “estimate,” “forecast,” “potential,” “predict,” "early clinician feedback," “expect,” “intend,” “guidance,” “outlook,” “optimistic,” “aspire,” “confident” or other forms of these words or similar expressions and include, but are not limited to, statements made by Mr. Zovighian, impact of Edwards’ therapies and innovation, including improving lives; access to care for underserved patients, changing the trajectory of their lives; and breaking down of barriers. No inferences or assumptions should be made from statements of past performance, efforts, or results which may not be indicative of future performance or results. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain, difficult to predict, and may be outside of the company’s control. The company's forward-looking statements speak only as of the date on which they are made and the company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the company does update or correct one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections.
Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements include risk and uncertainties associated with the risks detailed in the company's filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2025 and its other filings with the SEC. These filings, along with important safety information about our products, may be found at edwards.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20260226865431/en/
Media Contact: Amy Meshulam , media@edwards.com
Investor Contact: Investor_Relations@edwards.com
FAQ**
How does Edwards Lifesciences Corporation EW plan to leverage its partnerships to meet the goal of helping 2 million patients access structural heart treatment by 2030?
What metrics does Edwards Lifesciences Corporation EW use to measure the impact of its Every Heartbeat Matters initiative on underserved patients globally?
Can you elaborate on the breakthrough innovations mentioned by Edwards Lifesciences Corporation EW that are aimed at improving the lives of patients with structural heart disease?
What specific financial and systemic barriers does Edwards Lifesciences Corporation EW aim to address through its global health initiative, Every Heartbeat Matters?
**MWN-AI FAQ is based on asking OpenAI questions about Edwards Lifesciences Corporation (NYSE: EW).
NASDAQ: EW
EW Trading
-3.54% G/L:
$81.20 Last:
2,334,963 Volume:
$83 Open:
